GlassScriptPhysician profile
Palak Patel
NPI 1164958112
$1,657.36
in general payments reported to CMS, 2019-2025
21 companies · $518 in 2025
The $518 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $24.29 · 2023: $222 · 2024: $776 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441 · Education: $74.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.22 |
| Education | $74.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $333.09 | 2021-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $240.98 | 2021-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $186.30 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $141.87 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $129.08 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $86.48 | 2023 | Krystexxa |
| Baxter Healthcare | $84.40 | 2022-2024 | Renal - Pd |
| Opko Pharmaceuticals, LLC | $74.41 | 2023-2025 | Rayaldee |
| Vantive US Healthcare LLC | $56.36 | 2025 | Renal - Pd |
| Shield Therapeutics INC | $48.97 | 2024-2025 | |
| Glaxosmithkline, LLC. | $43.60 | 2024-2025 | Benlysta, Nucala |
| Alnylam Pharmaceuticals INC. | $37.59 | 2021-2025 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.75 | 2023-2024 | Jardiance |
| Fresenius USA Marketing, INC. | $25.00 | 2024 | Velphoro |
| Novo Nordisk INC | $23.61 | 2025 | Ozempic |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.92 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $22.26 | 2023 | Acthar |
| Vifor Pharma, INC. | $19.37 | 2021 | |
| Amgen INC. | $18.37 | 2024 | Tavneos |
| Aurinia Pharma U.S., INC. | $16.44 | 2024 | Lupkynis |
| Cormedix INC. | $13.51 | 2025 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palak Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.